Pharmacoeconomic Aspects in the Treatment of Curable and Incurable Cancer Viggo JønssonSimon R. ClausenMogens M. Hansen Leading Article 23 November 2012 Pages: 275 - 281
Do Physicians Take Cost Into Account When Making Prescribing Decisions? Petra DenigFlora M. Haaijer-Ruskamp Leading Article 23 November 2012 Pages: 282 - 290
Health-Related Quality-of-Life Evaluation in HIV-Infected Patients Josien B. de BoerFrits S. A. M. van DamMirjam A. G. Sprangers Review Article 23 November 2012 Pages: 291 - 304
Measuring Quality of Life in Patients with Depression or Anxiety Diane WhalleyStephen P. McKenna Review Article 23 November 2012 Pages: 305 - 315
Cost Utility of Chemotherapy and Best Supportive Care in Non-Small Cell Lung Cancer Wendy KennedyDaniel ReinharzJoseph Ayoub Original Research Articles 23 November 2012 Pages: 316 - 323
Theoretical Changes in Neonatal Hospitalisation Costs After the Introduction of Porcine-Derived Lung Surfactant (‘Curosurf’) Johannes Egberts Original Research Articles 23 November 2012 Pages: 324 - 342
Omeprazole or Ranitidine Plus Metoclopramide for Patients with Severe Erosive Oesophagitis Bernard S. BloomAlan L. HillmanGary J. Stever Original Research Articles 23 November 2012 Pages: 343 - 349
Costs of Antifungal Prophylaxis After Bone Marrow Transplantation Alan StewartRay PowlesJayesh Mehta Original Research Articles 23 November 2012 Pages: 350 - 361
The Pros and Cons of Generic Medicines Mark CampbellD. Nicholas BatemanAlison Beaney Correspondence 23 November 2012 Pages: 362 - 363
Erratum to Cost effectiveness of hepatitis A prevention in France C. A. SeveroF. FagnaniA. Lafuma Erratum 23 November 2012 Pages: 364 - 364